Product Description
Mechanisms of Action: Contrast Agent
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: European Medicines Agency | Germany | Ireland | Portugal
Approved Indications: None
Known Adverse Events: None
Company: NuvOx Pharma Pty
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Glioblastoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GBM | P1 |
Completed |
Glioblastoma |
2017-08-31 |
42% |